Tags

Type your tag names separated by a space and hit enter

Empagliflozin for the treatment of Type 2 diabetes.
Expert Rev Clin Pharmacol. 2014 May; 7(3):271-9.ER

Abstract

Diabetes and its complications account for a significant healthcare burden. There is increasing prevalence of diabetes and newer drugs are being investigated to improve outcomes. Sodium-glucose cotransporter inhibitors (SGLT2 inhibitors) are a newer class of medications, which prevent renal reabsorption of glucose and hence help in glycaemic control without significant risk of hypoglycaemia. Two drugs, namely dapagliflozin and canagliflozin have gained approval and empagliflozin is one of the advanced agents of this class. Early trials with empagliflozin have shown a stable pharmacokinetic profile and pharmacodynamic effects with significant SGLT2 selectivity. Clinical trials have shown improvement in glycaemic control and other benefits including weight loss and lowering of blood pressure. Ongoing trials and surveillance will provide answers about cardiovascular benefits, risk of osteoporosis and cancer.

Authors+Show Affiliations

Renal Research Lab, Kolling Institute of Medical Research, Sydney University, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24716752

Citation

Gangadharan Komala, Muralikrishna, and Amanda Mather. "Empagliflozin for the Treatment of Type 2 Diabetes." Expert Review of Clinical Pharmacology, vol. 7, no. 3, 2014, pp. 271-9.
Gangadharan Komala M, Mather A. Empagliflozin for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol. 2014;7(3):271-9.
Gangadharan Komala, M., & Mather, A. (2014). Empagliflozin for the treatment of Type 2 diabetes. Expert Review of Clinical Pharmacology, 7(3), 271-9. https://doi.org/10.1586/17512433.2014.908703
Gangadharan Komala M, Mather A. Empagliflozin for the Treatment of Type 2 Diabetes. Expert Rev Clin Pharmacol. 2014;7(3):271-9. PubMed PMID: 24716752.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Empagliflozin for the treatment of Type 2 diabetes. AU - Gangadharan Komala,Muralikrishna, AU - Mather,Amanda, Y1 - 2014/04/09/ PY - 2014/4/11/entrez PY - 2014/4/11/pubmed PY - 2014/12/15/medline SP - 271 EP - 9 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 7 IS - 3 N2 - Diabetes and its complications account for a significant healthcare burden. There is increasing prevalence of diabetes and newer drugs are being investigated to improve outcomes. Sodium-glucose cotransporter inhibitors (SGLT2 inhibitors) are a newer class of medications, which prevent renal reabsorption of glucose and hence help in glycaemic control without significant risk of hypoglycaemia. Two drugs, namely dapagliflozin and canagliflozin have gained approval and empagliflozin is one of the advanced agents of this class. Early trials with empagliflozin have shown a stable pharmacokinetic profile and pharmacodynamic effects with significant SGLT2 selectivity. Clinical trials have shown improvement in glycaemic control and other benefits including weight loss and lowering of blood pressure. Ongoing trials and surveillance will provide answers about cardiovascular benefits, risk of osteoporosis and cancer. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/24716752/Empagliflozin_for_the_treatment_of_Type_2_diabetes_ L2 - http://www.tandfonline.com/doi/full/10.1586/17512433.2014.908703 DB - PRIME DP - Unbound Medicine ER -